Jasper Therapeutics (NASDAQ:JSPR) Stock Falls 7% – Time to Sell?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) traded down 7% during mid-day trading on Tuesday. The company traded as low as $15.03 and last traded at $15.2310. 2,052 shares were traded during trading, a decline of 92% from the average session volume of 26,654 shares. The stock had previously closed at $16.37.

Analyst Ratings Changes

JSPR has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. William Blair assumed coverage on Jasper Therapeutics in a report on Wednesday, October 14th. They issued an “outperform” rating for the company. Piper Sandler assumed coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Wall Street Zen upgraded Jasper Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $220.00.

Jasper Therapeutics Trading Down 9.1%

The stock has a market capitalization of $495.24 million, a P/E ratio of -0.31 and a beta of 3.30. The stock’s fifty day moving average price is $17.34 and its two-hundred day moving average price is $24.81.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Friday, August 14th. The company reported ($3.00) EPS for the quarter, topping analysts’ consensus estimates of ($8.03) by $5.03. As a group, analysts expect that Jasper Therapeutics, Inc. will post -28.23 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation. Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.